Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients.

Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, Zaman T, Stone D, Mefford M, Morgello S, Singer EJ, Wolinsky SM, Gabuzda D. · 2008

Read Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. by Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, Zaman T, Stone D, Mefford M, Morgello S, Singer EJ, Wolinsky SM, Gabuzda D. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2424175.txt.

Introduction

Ancuta and co-authors linked gut leakage to brain disease in AIDS patients in 2008. In HIV infection, microbes leak products from the gut into blood, a process called microbial translocation. One such product, LPS, is a piece of bacterial wall that strongly activates monocytes, a type of white blood cell tied to HIV dementia.

They measured blood LPS in AIDS patients and checked monocyte activation markers. Patients with HIV-associated dementia had higher LPS than comparison groups, and the link held after accounting for virus levels and CD4 cell counts. High LPS came with raised sCD14 and LPS-binding protein, two activation signals, and low levels of antibodies that mop LPS up. Monocytes carried activation markers CD69 and HLA-DR at high levels. LPS was also higher in patients injecting heroin, drinking heavily, or co-infected with hepatitis C.

Catalog record

CREATORAncuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, Zaman T, Stone D, Mefford M, Morgello S, Singer EJ, Wolinsky SM, Gabuzda D.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE48 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2424175

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Microbial Translocation Is Associated with Increased Monocyte Activation and Dementia in AIDS Patients By Petronela Ancuta, Anupa Kamat, Kevin J Kunstman, Eun-Young Kim, Patrick Autissier, Alysse Wurcel, Tauheed Zaman, David Stone, Megan Mefford, Susan Morgello, Elyse J Singer, Steven M Wolinsky Published in: PLoS ONE DOI: 10.1371/journal.pone.0002516 ABSTRACT Abstract Elevated plasma lipopolysaccharide (LPS), an indicator of microbial translocation from the gut, is a likely cause of systemic immune activation in chronic HIV infection. LPS induces monocyte activation and trafficking into brain, which are key mechanisms in the pathogenesis of HIV-associated dementia (HAD). To determine whether high LPS levels are associated with increased monocyte activation and HAD, we obtained peripheral blood samples from AIDS patients and examined plasma LPS by Limulus amebocyte lysate (LAL) assay, peripheral blood monocytes by FACS, and soluble markers of monocyte activation by ELISA. Purified monocytes were isolated by FACS sorting, and HIV DNA and RNA levels were quantified by real time PCR. Circulating monocytes expressed high levels of the activation markers CD69 and HLA-DR, and harbored low levels of HIV compared to CD4+ T-cells. High plasma LPS levels were associated with increased plasma sCD14 and LPS-binding protein (LBP) levels, and low endotoxin core antibody levels. LPS levels were higher in HAD patients compared to control groups, and were associated with HAD independently of plasma viral load and CD4 counts. LPS levels were higher in AIDS patients using intravenous heroin and/or ethanol, or with Hepatitis C virus (HCV) co-infection, compared to control groups. These results suggest a role for elevated LPS levels in driving monocyte activation in AIDS, thereby contributing to the pathogenesis of HAD, and provide evidence that cofactors linked to substance abuse and HCV co-infection influence these processes. INTRODUCTION Immune activation is a strong predictor of HIV disease progression [1], [2]. Elevated plasma endotoxin (bacterial lipopolysaccharide, LPS, a component of Gram-negative bacteria), a consequence of translocation of bacterial products from a leaky gut, is a likely cause of immune activation in HIV infection [3]. LPS triggers monocyte (Mo) activation via CD14 and TLR4-mediated signaling, resulting in release of soluble CD14 and pro-inflammatory cytokines. Sustained Mo stimulation leads to LPS tolerance [4]. Brenchley et al. found correlations between plasma LPS levels, Mo tolerance to LPS ex vivo, and T-cell activation markers, and proposed that T-cell activation is an indirect consequence of LPS-mediated Mo stimulation [3]. Alterations in circulating Mo linked to HIV disease progression include increased expression of pro-inflammatory cytokines and Mo activation markers [5], [6], [7]. CD16/FcγRIII expression on Mo distinguishes a minor CD16+ subset [8], [9] that expresses higher TNF and IL-1 [5], and higher HLA-DR, CD40, and CD86 levels compared to CD16− Mo. CD16+ Mo represent 5–10% of circulating Mo in healthy individuals [8], but are dramatically expanded in HIV-infected patients [5], [10], particularly during progression to AIDS [6], [7]. Although Mo do not support productive HIV infection in vitro [11] and represent a minor viral reservoir in HIV-infected patients [12], [13], [14], CD16+ Mo may be preferentially susceptible to infection [14], [15], [16]. Furthermore, CD16+ Mo-derived macrophages form conjugates with T-cells that promote T-cell activation and HIV replication [17], [18]. Activated Mo play a key role in the pathogenesis of HIV-associated dementia (HAD) and minor cognitive motor disorder (MCMD) [7], [19], [20], [21], [22] by carrying virus into the CNS, supporting productive infection upon differentiation into macrophages, and producing neurotoxic factors [7], [21]. An increased frequency of CD16+/CD69+ activated Mo [5] was associated with HAD in the pre-HAART era [6], [7]. HAART decreases the frequency of CD16+ Mo [10], reduces HIV levels in brain, and improves neurocognitive function [19], but neurocognitive impairment (NCI) still occurs in ∼10–20% of AIDS patients [19], [20], [21]. Host factors that drive Mo activation in patients who develop HAD have not been defined. Here we investigated the relationship between plasma LPS, alterations in circulating Mo, and HAD in AIDS patients. High plasma LPS and LPS-binding protein (LBP) levels, together with low endotoxin core antibody (EndoCAb) levels, were associated with increased soluble markers of Mo activation and HAD. Plasma LPS levels were higher in AIDS subjects with IV heroin or ethanol abuse, or co-infection with Hepatitis C virus (HCV) compared to control groups. These findings suggest a role for elevated LPS levels in triggering Mo activation during HIV infection, thereby contributing to HAD pathogenesis, and identify cofactors that may influence these processes. MATERIALS AND METHODS Subjects AIDS patients with CD4 counts <300 cells/µl were recruited at the Lemuel Shattuck Hospital (n = 49) or at 4 sites in the National NeuroAIDS Tissue Consortium (NNTC) (Manhattan HIV Brain Bank, National Neurological AIDS Bank, California NeuroAIDS Tissue Network, Texas NeuroAIDS Research Center) (n = 70) with written informed consent and IRB approval. HIV-/HCV-uninfected blood was from Research Blood Components (Brighton, MA). Shattuck Hospital subjects were recruited based on presence or absence of an HAD diagnosis. NNTC subjects were selected by database searches based on patterns of substance abuse (determined by PRISM (psychiatric research interview for substance and mental disorders) diagnoses and urine tox screens) irrespective of HAD or other forms of NCI. HAD or MCMD diagnoses were determined using American Academy of Neurology diagnostic criteria [19], [23] and asymptomatic neurocognitive impairment (ANI) diagnosis was determined using HIV Neurobehavioral Research Center (HNRC) criteria [24] based on formal neurocognitive testing and/or neurological evaluation and lack of other known cause for NCI. Patients with severe psychiatric diagnoses that might confound neurological evaluation, a confounding neurological disorder (i.e., CNS opportunistic infection, brain neoplasm), or active bacterial or opportunistic infection were excluded. Antibodies Fluorochrome-conjugated Abs used for FACS analysis were CD14, CD16, CD19, CD33, CD16b, CD66b, CD56, and CD3 (Beckman Coulter); CD4, CCR5, CD69, and HLA-DR (BD Pharmingen). Cell sorting PBMC were isolated from peripheral blood by Ficoll-Paque centrifugation [17], [25]. Mo were isolated by negative selection using immunobeads (Miltenyi) [17], [25] or by FACS sorting. CD3+ T-cells were isolated using CD3 immunobeads (Miltenyi), and CD4+ T-cells were sorted by FACS. PBMC depleted of CD3+ T-cells were stained with PE-CD14 and PE-Cy5 CD16 Abs and FITC-conjugated Abs against T-cell (CD3), granulocyte (CD16b/CD66b), B cell (CD19), NK cell (CD56), and dendritic cell (CD1c) markers. Sorted T-cells and Mo were >98% pure as determined by FACS. Quantification of HIV DNA and RNA HIV DNA and RNA in CD4+ T-cells and Mo were quantified by real time PCR and RT-PCR (sensitive to 50 copies). Total DNA and RNA was isolated using Qiagen DNA-EZ and RNA-EZ isolation kits. DNA from 105 cells was amplified for 45 cycles using Taqman Universal PCR Master Mix (Applied Biosystems) and HIV Gag primers and probe [26]. Sequential dilutions of 8E5 cells were used to quantify Gag and CCR5 copy number. For qRT-PCR, RNA from 105 cells was reverse transcribed using the High Capacity cDNA Archive kit (Applied Biosystems) and amplified with HIV Gag primers and probes [26]. Isolation of replication-competent HIV CD4+ T-cells and Mo isolated from HIV-infected patients were cultured with Mo:CD4+ T-cell co-cultures from a HIV-uninfected donor pre-stimulated with PHA/IL-2 as described, a method that isolates both CCR5 and CXCR4-using HIV strains efficiently [17], [18], [27]. HIV p24 was quantified in culture supernatants by ELISA (Perkin Elmer). Quantification of plasma LPS, lipopolysaccaride binding-protein, IgM endotoxin core antibody, soluble CD14, IL-6, and

Read the complete text